Life Scientist > Biotechnology

Ballard wins Clunies Ross award

29 March, 2004 by Melissa Trudinger

South Australian biotechnologist Dr John Ballard has been awarded an ATSE Clunies Ross Award in recognition of his achievements in biochemical drug development over the course of his career, which has included starting three biotechnology companies, and more recently an investment organisation, BioAngels.


China OKs Brazil GMO soybean imports

26 March, 2004 by Staff Writers

China approved the importation of genetically modified soybeans from Brazil, which should allow shipments to begin as early as Tuesday for the world's largest soybean importer, according to Brazil's Agriculture Ministry.


Cogstate licences angiotensin compounds for Alzheimers

26 March, 2004 by Melissa Trudinger

Recently listed company CogState (ASX: CGS) has signed a licensing and research collaboration deal with Pacific Northwest Biotechnology (PNB) in the US to develop a drug to treat Alzheimer's disease.


Allergan files INDs for Peplin's topical treatment

25 March, 2004 by Renate Krelle

Peplin Biotech (ASX: PEP) today announced the filing of three separate Investigational New Drug (IND) applications with the US Food and Drug Administration for a topical formulation of its lead compound PEP005.


Select Vaccines signs agreement to develop Hep C test

25 March, 2004 by Melissa Trudinger

Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.


Prana appoints US analyst to board

25 March, 2004 by Melissa Trudinger

Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.


Bracks bans GMHT canola until 2008

25 March, 2004 by Graeme O'Neill

The Victorian Government has announced a four-year, legislated moratorium on commercial cropping of genetically modified herbicide-tolerant (GMHT) canola.


Biota signs new flu diagnostic agreement

24 March, 2004 by Melissa Trudinger

Biota (ASX:BTA) has signed a new agreement with its US-based flu diagnostics partner Thermo Electron giving it a profit share in a second influenza diagnostic kit, FLU OIA A/B.


GM banned in WA

23 March, 2004 by Iain Scott

Western Australian premier Geoff Gallop has announced that genetically modified food crops will not be grown in the state.


Psivida subsidiary signs manufacturing deal

23 March, 2004 by Melissa Trudinger

PsiMedica, the UK subsidiary of Perth-based nanotechnology company Psivida (ASX:PSD), has signed a three-year manufacturing agreement with nuclear pharmaceuticals company Auriga Medical as it gears up to start Phase II clinical trials of its BioSilicon-based brachytherapy product in Singapore later this year.


Axon accepts takeover bid

23 March, 2004 by Renate Krelle

Microarray and cellular screening company Axon Instruments (ASX:AXN) has accepted a friendly takeover offer from California-based Molecular Diagnostics.


Sydney firm develops new DNA ID method

23 March, 2004 by Melissa Trudinger

Sydney-based company Human Genetic Signatures (HGS) has developed a new method for identifying DNA methylation patterns -- an epigenetic phenomenon thought to play a role in ageing and disease.


Amrad reveals share buyback scheme

22 March, 2004 by Melissa Trudinger

Amrad (ASX:AML) has announced plans to buy back up to 10 per cent of its shares over the next 12 months, at a cost of around AUD$9 million at the current share price of AUD$0.69.


GM crops: Australia waits for the world

19 March, 2004 by Graeme O'Neill

Monday is M-Day for Victoria: will the Bracks government end its 12-month, voluntary moratorium on commercial cropping of genetically modified canola, imposed in May last year?


Greenpeace accuses CSIRO of suppressing GE reports

17 March, 2004 by Graeme O'Neill

Greenpeace Australia-Pacific has accused the CSIRO of suppressing several reports on environmental risks associated with genetically engineered crops, and alleged the Office of the Gene Technology Regulator was failing to acknowledge and assess “serious hazards” before granting GE crop licenses.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd